Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Biohaven completed enrollment in the pivotal RISE3 Phase 2/3 trial of opakalim for refractory focal epilepsy; top-line results are expected in 2H 2026. In the ongoing focal epilepsy OLE, 54% of patients on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency over any consecutive six months vs pre-randomization baseline, with nervous system adverse events reported at low levels (e.g., 5% dizziness, 4% fatigue) and ~95% double-blind completion/rollover rates—supporting a favorable tolerability profile. The update is a meaningful clinical milestone that should bolster investor confidence ahead of 2H 2026 readouts.

Analysis

This is more of a de-risking event than a fundamental re-rate. Completing enrollment reduces execution risk and pushes the story from "can they run the trial?" to "does the drug beat placebo on a noisy endpoint?" — but the market should not pay full probability for that yet, because epilepsy readouts are highly sensitive to placebo response, background ASM mix, and site-level variability. The OLE signal is directionally useful for tolerability, but it is still a responder-enriched population, so it supports a cleaner commercial narrative more than it proves broad efficacy.

If the tolerability profile holds, the real upside is not just approval odds; it is label quality and adoption speed. A once-daily, low-CNS-burden adjunctive option could take share from branded ASMs where dizziness/somnolence limit persistence, especially in patients cycling through multiple add-ons. That creates second-order pressure on competitors’ net pricing and discontinuation rates, while also improving Biohaven’s negotiating leverage for a future CNS franchise beyond this single asset.

The main risk is duration. There is almost no reason to chase this purely on a near-term press release unless the stock has not yet fully discounted the 2H 2026 catalyst. The thesis can be falsified quickly by a weak interim signal from RISE2 or any hint that efficacy is concentrated only in the most compliant OLE patients. Over 6-18 months, the bigger issue is financing: a positive program can still underperform if the market starts pricing in additional dilution before the readout.

Key Decisions for Investors

• Tactically hold or add BHVN on weakness only if the market sells the de-risking news; this is a months-long catalyst trade, not a day-one momentum chase. Best entry is post-rally fade if implied probability of success is still below the peer-group average; cut if the stock fails to hold the breakout level after the next clinical update.
• Own BHVN vs. XBI as a relative-value expression: long BHVN / short XBI for 3-6 months to isolate asset-specific de-risking while avoiding broad biotech beta. Falsify if BHVN underperforms XBI after the market digests enrollment, which would signal that investors see this as just another binary neuro readout.
• Watch for a paired trade against branded epilepsy incumbents if commercialization data improves: long BHVN, short a branded ASM basket proxy if the next efficacy update confirms low CNS adverse events and durable responder persistence. The trade only works if the readout suggests adherence and retention, not merely statistical significance.
• Set an alert for any capital-raise language before top-line data; if dilution risk rises, trim or hedge BHVN because pre-readout financing can cap multiple expansion even with good clinical sentiment.
• No options recommendation yet unless the stock is still cheap relative to the 2H 2026 readout date; if implied volatility remains muted, consider a long-dated call spread only after the next data point, not on this enrollment headline alone.